One-stop-shop for artificial intelligence applications launched.
CHICAGO - Finding and purchasing AI imaging applications just got a bit easier.
IBM Watson Health Imaging announced the launch of its Imaging AI Marketplace at this year’s annual meeting of the Radiological Society of North America in Chicago. The single-source solution marketplace is designed to help streamline the process of locating, buying, deploying, and managing the ever-growing options for AI Imaging applications. The one-stop-shop experience simplifies a process that can be complex and resource-draining.
As a carefully-controlled database of AI applications, the IBM Imaging AI Marketplace only includes solutions that have been cleared by the U.S. Food & Drug Administration, as well as AI solutions developed by Watson Health. This vetted catalog offers solutions for a wide range of specialties and modalities to meet customer needs.
In addition to this extensive collection of applications, the Imaging AI Marketplace also helps customers deploy AI imaging applications into their existing clinical workflow, potentially minimizing disruptions to physician productivity, and maximizing patient care.
Customers can access the Imaging AI Marketplace via IBM Watson Health’s iConnect™ Enterprise Archive.
To date, IBM Watson Health Imaging has several vendor partners for its Imaging AI Marketplace. So far, the company has partnered with Circle Cardiovascular Imaging, DiA Imaging Analysis Ltd., MaxQAI, Quantib BV, VIDA LungPrint.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.